Download PDF
CC BY 4.0 · TH Open 2019; 03(02): e180-e189
DOI: 10.1055/s-0039-1692989
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Potential Antimigraine Effects of Warfarin: An Exploration of Biological Mechanism with Survey of Patients

Benjamin Nilsson
1   Alberta Health Services, Edmonton, Alberta, Canada
2   Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
,
Valentina Back
2   Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
3   Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
,
Ran Wei
3   Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
4   Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
,
Frances Plane
3   Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
4   Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
,
Paul Jurasz   *
2   Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada
3   Cardiovascular Research Centre, University of Alberta, Edmonton, Alberta, Canada
4   Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
5   Alberta Mazankowski Heart Institute, University of Alberta, Edmonton, Alberta, Canada
,
Tammy J. Bungard   *
6   Department of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
› Author Affiliations Funding This work was funded by grants from the Canadian Institutes of Health Research MOP-130289 (P.J.). We thank S. Simpson for assistance with survey.
Further Information

Publication History

01 April 2019

20 May 2019

Publication Date:
21 June 2019 (online)

Also available at
   Permissions and Reprints

Abstract

Case reports suggest a link between anticoagulant use and improved migraine symptoms, and a role for platelet-induced cerebral vasoconstriction in migraine pathobiology. Hence, we investigated the mechanism by which warfarin may affect migraine symptoms and whether there is a change in migraine symptomology in patients initiating oral anticoagulants, most commonly warfarin. The effects of warfarin on human platelet aggregation and secretion as well as platelet-induced rat cerebral artery vasoconstriction were studied. A survey of migraine and symptom change after starting or stopping oral anticoagulants was also conducted. Warfarin inhibited platelet aggregation and 5-hydroxytryptamine (5-HT) secretion in a concentration-dependent manner. Warfarin-inhibited platelet secretion products constricted middle cerebral arteries from male but not from female rats. For the survey, patient demographic information, migraine and medical history, and Migraine Disability Assessment Score (MIDAS) changes were collected. Out of 175 consenting, 40 respondents met the criteria for migraine and completed the survey. A total of 11 patients reported migraine symptom change, all coinciding with starting warfarin. Of those having symptom and MIDAS improvement, most were female with migraines with aura, whereas those worsening were male with fewer having migraine with aura. Of those reporting migraine symptom change with warfarin, female sex may be associated with improved MIDAS, and those experiencing an aura component are more likely to report a symptom change. Warfarin-mediated symptom improvement in females may occur due to inhibition of platelet 5-HT secretion and a lower sensitivity of female cerebral blood vessels to platelet-derived 5-HT-induced vasoconstriction.

Keywords

warfarin - migraine - platelets - serotonin - blood vessels

* Co-senior authors.


 

  • References

  • 1 Wolff HG. Headache and Other Pain. 2nd ed. New York, NY: Oxford University Press; 1963
    Google Scholar
  • 2 Andersen AR, Friberg L, Olsen TS, Olesen J. Delayed hyperemia following hypoperfusion in classic migraine. Single photon emission computed tomographic demonstration. Arch Neurol 1988; 45 (02) 154-159
    CrossrefPubMedGoogle Scholar
  • 3 Olesen J, Friberg L, Olsen TS. , et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990; 28 (06) 791-798
    CrossrefPubMedGoogle Scholar
  • 4 Ferrari MD. Migraine. Lancet 1998; 351 (9108): 1043-1051
    CrossrefPubMedGoogle Scholar
  • 5 Danese E, Montagnana M, Lippi G. Platelets and migraine. Thromb Res 2014; 134 (01) 17-22
    CrossrefPubMedGoogle Scholar
  • 6 Buttinelli C, Lazzaro MP, Lenzi GL, Paolucci S, Prencipe M. Correlation between migraine and circulating platelet aggregates. Cephalalgia 1985; 5 (02) (Suppl. 02) 87-88
    CrossrefPubMedGoogle Scholar
  • 7 Lechner H, Ott E, Fazekas F, Pilger E. Evidence of enhanced platelet aggregation and platelet sensitivity in migraine patients. Cephalalgia 1985; 5 (02) (Suppl. 02) 89-91
    CrossrefPubMedGoogle Scholar
  • 8 Tietjen GE, Al-Qasmi MM, Athanas K, Utley C, Herial NA. Altered hemostasis in migraineurs studied with a dynamic flow system. Thromb Res 2007; 119 (02) 217-222
    CrossrefPubMedGoogle Scholar
  • 9 Mück-Seler D, Deanović Z, Dupelj M. Platelet serotonin (5-HT) and 5-HT releasing factor in plasma of migrainous patients. Headache 1979; 19 (01) 14-17
    CrossrefPubMedGoogle Scholar
  • 10 Benemei S, Cortese F, Labastida-Ramírez A. , et al; School of Advanced Studies of the European Headache Federation (EHF-SAS). Triptans and CGRP blockade: impact on the cranial vasculature. J Headache Pain 2017; 18 (01) 103
    CrossrefPubMedGoogle Scholar
  • 11 Savi LT, Condello V, Bert F, Pinessi L. Prophylaxis of migraine with aura: a place for acetylsalicylic acid. J Headache Pain 2013; 14 (Suppl. 01) P195
    CrossrefPubMedGoogle Scholar
  • 12 Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. Heart 2005; 91 (09) 1173-1175
    CrossrefPubMedGoogle Scholar
  • 13 Suresh CG, Neal D, Coupe MO. Warfarin treatment and migraine. Postgrad Med J 1994; 70 (819) 37-38
    CrossrefPubMedGoogle Scholar
  • 14 van Puijenbroek EP, Egberts AC, Trooster JF, Zomerdijk J. Reduction of migrainous headaches during the use of acenocoumarol. Headache 1996; 36 (01) 48-48
    CrossrefPubMedGoogle Scholar
  • 15 Fragoso YD. Reduction of migraine attacks during the use of warfarin. Headache 1997; 37 (10) 667-668
    CrossrefPubMedGoogle Scholar
  • 16 Souza JA, Moreira Filho PF, Jevoux Cda C, Martins GF, Pitombo AB. Remission of refractory chronic cluster headache after warfarin administrations: case report. Arq Neuropsiquiatr 2004; 62 (04) 1090-1091
    CrossrefPubMedGoogle Scholar
  • 17 Russo A, Santi S, Gueraldi D, De Paola M, Zani F, Pini LA. An unusual case report on the possible role of Warfarin in migraine prophylaxis. Springerplus 2013; 2 (01) 48
    CrossrefPubMedGoogle Scholar
  • 18 Nilsson BG, Bungard TJ. A case of migraine with aura resolving on warfarin but not on apixaban. Headache 2017; 57 (10) 1614-1617
    CrossrefPubMedGoogle Scholar
  • 19 Teng CM, Li HL, Wu TS, Huang SC, Huang TF. Antiplatelet actions of some coumarin compounds isolated from plant sources. Thromb Res 1992; 66 (05) 549-557
    CrossrefPubMedGoogle Scholar
  • 20 Leoncini G, Signorello MG, Bruzzese D, Di Braccio M, Grossi GC, Roma G. Mechanisms involved in the antiplatelet activity of 8-methyl-4-(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414). Biochem Pharmacol 2004; 67 (05) 911-918
    CrossrefPubMedGoogle Scholar
  • 21 Macáková K, Řeháková Z, Mladěnka P. , et al. In vitro platelet antiaggregatory properties of 4-methylcoumarins. Biochimie 2012; 94 (12) 2681-2686
    CrossrefPubMedGoogle Scholar
  • 22 Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009; 339: b3914
    CrossrefPubMedGoogle Scholar
  • 23 Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S. Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 2010; 123 (07) 612-624
    CrossrefPubMedGoogle Scholar
  • 24 Moncada de la Rosa C, Radziwon-Balicka A, El-Sikhry H. , et al. Pharmacologic protein kinase Cα inhibition uncouples human platelet-stimulated angiogenesis from collagen-induced aggregation. J Pharmacol Exp Ther 2013; 345 (01) 15-24
    CrossrefPubMedGoogle Scholar
  • 25 Stewart WF, Lipton RB, Whyte J. , et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999; 53 (05) 988-994
    CrossrefPubMedGoogle Scholar
  • 26 Wammes-van der Heijden EA, Tijssen CC, van't Hoff AR, Egberts AC. A thromboembolic predisposition and the effect of anticoagulants on migraine. Headache 2004; 44 (05) 399-402
    CrossrefPubMedGoogle Scholar
  • 27 Di Braccio M, Grossi G, Roma G, Grazia Signorello M, Leoncini G. Synthesis and in vitro inhibitory activity on human platelet aggregation of novel properly substituted 4-(1-piperazinyl)coumarins. Eur J Med Chem 2004; 39 (05) 397-409
    CrossrefPubMedGoogle Scholar
  • 28 Ishimoto Y, Nakano T. Release of a product of growth arrest-specific gene 6 from rat platelets. FEBS Lett 2000; 466 (01) 197-199
    CrossrefPubMedGoogle Scholar
  • 29 Angelillo-Scherrer A, de Frutos P, Aparicio C. , et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001; 7 (02) 215-221
    CrossrefPubMedGoogle Scholar
  • 30 Chan E, McLachlan AJ, Pegg M, MacKay AD, Cole RB, Rowland M. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994; 37 (06) 563-569
    CrossrefPubMedGoogle Scholar
  • 31 Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998; 46 (01) (Suppl. 01) 45-50
    CrossrefPubMedGoogle Scholar
  • 32 Shaik AN, Grater R, Lulla M. , et al. Comparison of enzyme kinetics of warfarin analyzed by LC-MS/MS QTrap and differential mobility spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016; 1008: 164-173
    CrossrefPubMedGoogle Scholar
  • 33 Chen YL, Wang TC, Liang SC, Teng CM, Tzeng CC. Synthesis and evaluation of coumarin alpha-methylene-gamma-butyrolactones: a new class of platelet aggregation inhibitors. Chem Pharm Bull (Tokyo) 1996; 44 (08) 1591-1595
    CrossrefPubMedGoogle Scholar
  • 34 Kovacs IB, Murphy M, Barin E, Rees GM. Effect of warfarin on arterial thrombogenesis: problems of monitoring. Am J Hematol 1993; 42 (03) 322-327
    CrossrefPubMedGoogle Scholar
  • 35 Newland H, Nordöy A. Effect of large doses of warfarin sodium on haemostasis and on ADP-induced platelet aggregation in vivo in the rat. A survey of experimental thrombosis and coumarin anticoagulant therapy. Cardiovasc Res 1967; 1 (04) 362-370
    CrossrefPubMedGoogle Scholar
  • 36 Woronowicz K, Dilks JR, Rozenvayn N. , et al. The platelet actin cytoskeleton associates with SNAREs and participates in alpha-granule secretion. Biochemistry 2010; 49 (21) 4533-4542
    CrossrefPubMedGoogle Scholar
  • 37 Nilsson T, Longmore J, Shaw D, Olesen IJ, Edvinsson L. Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry. Br J Pharmacol 1999; 128 (06) 1133-1140
    CrossrefPubMedGoogle Scholar
  • 38 Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265 (2, Pt 2): H586-H592
    PubMedGoogle Scholar
  • 39 Ahnstedt H, Cao L, Krause DN. , et al. Male-female differences in upregulation of vasoconstrictor responses in human cerebral arteries. PLoS One 2013; 8 (04) e62698
    CrossrefPubMedGoogle Scholar
  • 40 Hansen JM, Schankin CJ. Cerebral hemodynamics in the different phases of migraine and cluster headache. J Cerebral Blood Flow Metabol 2019; 39 (04) 595-609
    CrossrefPubMedGoogle Scholar
  • 41 Morales-Asín F, Iñiguez C, Cornudella R, Mauri JA, Espada F, Mostacero EE. Patients with acenocoumarol treatment and migraine. Headache 2000; 40 (01) 45-47
    CrossrefPubMedGoogle Scholar
  • 42 Maggioni F, Bruno M, Mainardi F, Lisotto C, Zanchin G. Migraine responsive to warfarin: an update on anticoagulant possible role in migraine prophylaxis. Neurol Sci 2012; 33 (06) 1447-1449
    CrossrefPubMedGoogle Scholar
  • 43 Cuadrado MJ, Khamashta MA, Hughes GRV. Migraine and stroke in young women. QJM 2000; 93 (05) 317-318
    CrossrefPubMedGoogle Scholar
  • 44 White RE. Estrogen and vascular function. Vascul Pharmacol 2002; 38 (02) 73-80
    PubMedGoogle Scholar
  • 45 Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ 2017; 8 (01) 33
    CrossrefPubMedGoogle Scholar
  • 46 Viguier F, Michot B, Hamon M, Bourgoin S. Multiple roles of serotonin in pain control mechanisms--implications of 5-HT7 and other 5-HT receptor types. Eur J Pharmacol 2013; 716 (1-3): 8-16
    CrossrefPubMedGoogle Scholar
  • 47 Segelcke D, Messlinger K. Putative role of 5-HT2B receptors in migraine pathophysiology. Cephalalgia 2017; 37 (04) 365-371
    CrossrefPubMedGoogle Scholar
  • 48 Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ. Migraine and incidence of ischemic stroke: a nationwide population-based study. Cephalalgia 2017; 37 (04) 327-335
    CrossrefPubMedGoogle Scholar
  • 49 Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ. Association between migraine and risk of venous thromboembolism: a nationwide cohort study. Headache 2016; 56 (08) 1290-1299
    CrossrefPubMedGoogle Scholar